Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 1,229 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $16.00, for a total value of $19,664.00. Following the completion of the sale, the insider now directly owns […]
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) gapped up before the market opened on Monday after HC Wainwright raised their price target on the stock from $45.00 to $50.00. The stock had previously closed at $13.60, but opened at $15.13. Day One Biopharmaceuticals shares last traded at $15.54, with a volume of […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) shares dropped 7.4% during mid-day trading on Wednesday . The company traded as low as $12.00 and last traded at $12.00. Approximately 337,117 shares were traded during trading, a decline of 55% from the average daily volume of 747,440 shares. The stock had previously closed at $12.96. […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) has earned an average rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 9,120,000 shares, an increase of 16.0% from the April 15th total of 7,860,000 shares. Based on an average daily trading volume, of 778,000 […]